PEDIATRICS Vol. 87 No. 3 March 1991, pp. 377-386
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dunn, M. S.
Right arrow Articles by Possmayer, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dunn, M. S.
Right arrow Articles by Possmayer, F.

Bovine Surfactant Replacement Therapy in Neonates of Less Than 30 Weeks' Gestation: a Randomized Controlled Trial of Prophylaxis Versus Treatment

Michael S. Dunn MD, FRCPC1, Andrew T. Shennan MB, MRCP(UK), FRCPC1, Denise Zayack RN1, and Fred Possmayer PhD2

1 From the Regional Perinatal Unit, University of Toronto Perinatal Complex, Women's College Hospital, Toronto, Ontario
2 University of Western Ontario, London, Ontario, Canada

The influence of the timing of surfactant replacement therapy for the treatment of neonatal respiratory distress syndrome was evaluated in a study of 182 neonates of less than 30 weeks' gestation who were randomly assigned prior to delivery to one of three study groups: control (dummy instillation of air given at birth), early surfactant (surfactant given at birth), or late surfactant (surfactant given at <6 hours of age). Subjects in the late surfactant group could avoid treatment if they had a clear chest roentgenogram and required no supplemental oxygen at a mean airway pressure of less than 7 cm of water. All treated neonates were eligible to receive up to three additional doses during the first 5 days of life. The three groups were comparable with respect to birth weight, gestational age, and other perinatal parameters with the exception of a lower cord arterial pH and 1-minute Apgar score in the early surfactant group. Of the 60 neonates randomly assigned to late treatment, 29 (48%) were deemed surfactant sufficient and thereby avoided treatment; the other 31 received their first dose at a mean age of 2.9 hours. There was a significant improvement in gas exchange during the first week of life in both surfactant groups compared with the control group, reflected by differences in fraction of inspired oxygen, arterial/alveolar Po2, and ventilation index (peak pressure x rate on the ventilator) (P < .001). Surfactant therapy also resulted in a lower incidence of pulmonary air leak and severe chronic lung disease (defined as requirement for respiratory support beyond 36 weeks post-conceptional age). There were no differences between early and late surfactant groups in any of these parameters. The only statistically significant difference between the surfactant groups was that the early group had a higher incidence of mild chronic lung disease (respiratory support beyond 28 days of age) than the late treatment group (P < .005). Neonates in the late treatment group were extubated earlier and had a shorter neonatal intensive care unit stay than control neonates (P < .05), whereas those in the early group were not significantly different from control neonates in these parameters. It is concluded that replacement therapy with bovine lung surfactant extract in neonates of less than 30 weeks' gestation results in decreased oxygen and ventilatory requirements during the first week of life and a lower incidence of pulmonary air leak and severe chronic lung disease. Comparable short-term effects were seen whether a prophylactic or treatment approach was used, but there was a lower incidence of mild chronic lung disease with late treatment. There appears to be no clinical justification for routinely using a prophylactic approach to surfactant replacement therapy in this population of neonates.

Key Words: pulmonary surfactant • respiratory distress syndrome • bronchopulmonary dysplasia • neonates

Submitted on August 20, 1990
Accepted on October 23, 1990




This article has been cited by other articles:


Home page
 PediatricsHome page
W. A. Engle and and the Committee on Fetus and Newborn
Surfactant-Replacement Therapy for Respiratory Distress in the Preterm and Term Neonate
Pediatrics, February 1, 2008; 121(2): 419 - 432.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
C. Geary, M. Caskey, R. Fonseca, and M. Malloy
Decreased Incidence of Bronchopulmonary Dysplasia After Early Management Changes, Including Surfactant and Nasal Continuous Positive Airway Pressure Treatment at Delivery, Lowered Oxygen Saturation Goals, and Early Amino Acid Administration: A Historical Cohort Study
Pediatrics, January 1, 2008; 121(1): 89 - 96.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
M. Ghodrat
Lung surfactants.
Am. J. Health Syst. Pharm., August 15, 2006; 63(16): 1504 - 1521.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
V. P. A. Rasaiah, J. L. Malloy, J. F. Lewis, and R. A. W. Veldhuizen
Early surfactant administration protects against lung dysfunction in a mouse model of ARDS
Am J Physiol Lung Cell Mol Physiol, May 1, 2003; 284(5): L783 - L790.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
T. Nakamura, J. Malloy, L. McCaig, L.-J. Yao, M. Joseph, J. Lewis, and R. Veldhuizen
Mechanical ventilation of isolated septic rat lungs: effects on surfactant and inflammatory cytokines
J Appl Physiol, August 1, 2001; 91(2): 811 - 820.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
D. A. Osborn, H. E. Jeffery, S. L. Bredemeyer, J. M. Polverino, and S. Reid
Targeted Early Rescue Surfactant in Ventilated Preterm Infants Using the Click Test
Pediatrics, September 1, 2000; 106(3): 30e - 30.
[Abstract] [Full Text]

Home page
 Am. J. Respir. Crit. Care Med.Home page
J. LEWIS, L. MCCAIG, D. HÄFNER, R. SPRAGG, R. VELDHUIZEN, and C. KERR
Dosing and Delivery of a Recombinant Surfactant in Lung-injured Adult Sheep
Am. J. Respir. Crit. Care Med., March 1, 1999; 159(3): 741 - 747.
[Abstract] [Full Text]

Home page
 PediatricsHome page
H. Verder, P. Albertsen, F. Ebbesen, G. Greisen, B. Robertson, A. Bertelsen, L. Agertoft, B. Djernes, E. Nathan, and J. Reinholdt
Nasal Continuous Positive Airway Pressure and Early Surfactant Therapy for Respiratory Distress Syndrome in Newborns of Less Than 30 Weeks' Gestation
Pediatrics, February 1, 1999; 103(2): 24e - 24.
[Abstract] [Full Text]

Home page
 PediatricsHome page
L. Gortner, R. R. Wauer, H. Hammer, G.-J. Stock, F. Heitmann, H. L. Reiter, P. G. Kühl, J. C. Möller, H.-J. Friedrich, I. Reiss, et al.
Early Versus Late Surfactant Treatment in Preterm Infants of 27 to 32 Weeks' Gestational Age: A Multicenter Controlled Clinical Trial
Pediatrics, November 1, 1998; 102(5): 1153 - 1160.
[Abstract] [Full Text]

Home page
 PediatricsHome page
J. W. Kendig, R. M. Ryan, R. A. Sinkin, W. M. Maniscalco, R. H. Notter, R. Guillet, C. Cox, H. S. Dweck, M. J. Horgan, L. J. Reubens, et al.
Comparison of Two Strategies for Surfactant Prophylaxis in Very Premature Infants: A Multicenter Randomized Trial
Pediatrics, June 1, 1998; 101(6): 1006 - 1012.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
R. A. Sinkin, B. M. Kramer, J. L. Merzbach, G. J. Myers, J. G. Brooks, D. R. Palumbo, C. Cox, J. W. Kendig, C. E. Mercier, and D. L. Phelps
School-age Follow-up of Prophylactic Versus Rescue Surfactant Trial: Pulmonary, Neurodevelopmental, and Educational Outcomes
Pediatrics, May 1, 1998; 101 (5): e11 - e11.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
J. A. Stiskal, M. S. Dunn, A. T. Shennan, K. K. E. O'Brien, E. N. Kelly, R. I. Koppel, D. W. Cox, S. Ito, S. L. Chappel, and M. Rabinovitch
alpha 1-Proteinase Inhibitor Therapy for the Prevention of Chronic Lung Disease of Prematurity: A Randomized, Controlled Trial
Pediatrics, January 1, 1998; 101(1): 89 - 94.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
M. L. Hudak, D. J. Martin, E. A. Egan, E. J. Matteson, J. Cummings, A. L. Jung, L. V. Kimberlin, R. L. Auten, A. A. Rosenberg, J. M. Asselin, et al.
A Multicenter Randomized Masked Comparison Trial of Synthetic Surfactant Versus Calf Lung Surfactant Extract in the Prevention of Neonatal Respiratory Distress Syndrome
Pediatrics, July 1, 1997; 100(1): 39 - 50.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
J. Egberts, R. Brand, H. Walti, G. Bevilacqua, G. B. MD, and F. Gardini
Mortality, Severe Respiratory Distress Syndrome, and Chronic Lung Disease of the Newborn Are Reduced More After Prophylactic Than After Therapeutic Administration of the Surfactant Curosurf
Pediatrics, July 1, 1997; 100(1): e4 - e4.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child. Fetal Neonatal Ed.Home page
C J Morley
Systematic review of prophylactic vs rescue surfactant
Arch. Dis. Child. Fetal Neonatal Ed., July 1, 1997; 77(1): 70F - 74.
[Full Text]

Home page
 NEJMHome page
A. H. Jobe
Pulmonary Surfactant Therapy
N. Engl. J. Med., March 25, 1993; 328(12): 861 - 868.
[Full Text]